SCTX CRISPR therapies show promise for cardiovascular prevention
SCTX’s novel CRISPR-based platform for cardiovascular and metabolic diseases is advancing, with lead programs targeting LDL-C, Lp(a) and triglycerides. Early data point to durable efficacy and safety, backed by major partnerships.